Cardiovascular Journal of Africa: Vol 28 No 2 (March/April 2017)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 2, March/April 2017

AFRICA

INTERHEART study investigators. Obesity and the risk of myocardial

infarction in 27,000 participants from 52 countries: a case- control study.

Lancet

2005;

366

(9497): 1640–1649.

16. Report of a WHO consultation. Obesity: prevalence and managing the

global epidemic.

World Health Org Tech Rep Ser

2000;

894

: i–xii, 1–253).

17. MedCalc

1993–2015, Version 15.2.2 Altman DG. Practical Statistics for

Medical Research. London: Chapman and Hall, 1991.

18. Nnyepi MS, Gwisai N, Lekgoa M, Seru T. Evidence of nutrition transi-

tion in Southern Africa.

Proc Nutr Soc

2015; Feb 17: 1–9 Epub ahead

of print.

19. World Health Organization 2009. WHO Global InfoBase.

20. Jansen I, Katzmarzyk PT, Ross R. Body mass index, waist circumfer-

ence, and health risk: evidence in support of current National Institutes

of Health Guidelines.

Arch Intern Med

2002;

162

(18): 2074–2079.

21. Balkau B, Charles MA. Comment on the provisional report of WHO

consultation. European Group for the Study of Insulin Resistance

(EGIR).

Diabet Med

1999;

: 442–443.

22. Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL,

et al

. Optimal cut-

off values for obesity: using simple anthropometric indices to predict

cardiovascular risk factors in Taiwan.

In J Obes Relat Metab Disord

2002;

: 1232–1238.

23. Expert panel on detection, evaluation, and treatment of high blood

cholesterol in adults. Executive summary of the third report of the

National Cholesterol Education Program (NCEP) expert panel on

detection, evaluation, and treatment of high blood cholesterol in adults

(Adult Treatment Panel III).

J Am Med Assoc

2001;

285

: 2486–2497.

24. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey

et al.

, prospective studies collaborators. Body mass index and cause-

specific mortality in 900,000 adults: collaborative analyses of 57

prospective studies.

Lancet

2009;

373

(9669): 1083–1096.

25. The Practical Guide: identification, evaluation, and treatment of

overweight and obesity in adults.

http://www.nhbli.nih.gov/guidelines/

obesity/prctgd_c.pdf (Accessed 06 November 2013).

26. Macal CM, North MJ. Tutorial on agent-based modeling and simula-

tion

. J Simulation

2010;

: 151–162. doi:10.1057/jos.2010.3.

27. Homer JB, Hirsch GM. System dynamics modeling for public health:

background and opportunities.

Am J Public Health

2006;

: 452–458.

doi:10.2105/AJPH.2005.062059.

Confidence Through Clinical

and Real World Experience

1-3

Millions of Patients Treated Across Multiple Indications

#1 NOAC prescribed by Cardiologists

*Impact RX Data Oct - Dec 2015

NOAC: Non Vitamin K Oral Anticoagulant

REFERENCES: 1.

Patel M.R., Mahaffey K.W., Garg J.

et al.

Rivaroxaban versus warfarin in non-valvular atrial fi brillation.

N Engl J Med

. 2011;365(10):883–91.

Tamayo S., Peacock W.F., Patel M.R.,

et al.

Characterizing major bleeding in patients

with nonvalvular atrial fi brillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.

Clin Cardiol

. 2015;38(2):63–8.

Camm A.J., Amarenco P., Haas S.

et al.

XANTUS: A Real-World, Prospective, Observational Study.

Calculation

based on IMS Health MIDAS, Database: Monthly Sales December 2015.

S4 XARELTO

15: Each film-coated tablet contains rivaroxaban 15 mg. Reg. No: 46/8.2/0111; Namibia S2 : 12/8.2/0006; Botswana S2 : BOT1302296

S4 XARELTO

20: Each film-coated tablet contains rivaroxaban 20 mg. Reg. No: 46/8.2/0112; Namibia S2 : 12/8.2/0007; Botswana S2 : BOT1302297

PHARMACOLOGICAL CLASSIFICATION:

A.8.2 Anticoagulants.

INDICATIONS:

(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis (DVT) and for the prevention

of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).

HCR:

Bayer (Pty) Ltd, Co. Reg. No.:

1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: +27 (0) 11 921 5044 Fax: +27 (0) 11 921 5041. For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC).

L.ZA.MKT.GM.01.2016.1265